

REGULAR ARTICLE

Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes

Marshall L Summar (Marshall.summar@vanderbilt.edu)¹, Dries Dobbelaer², Saul Brusilow³, Brendan Lee⁴

1.Vanderbilt University Medical Center, Nashville, TN, USA

2.Hospital University Medical Center of Lille, Lille Cedex, France

3.Johns Hopkins Medical Center, Baltimore, MD, USA

4.Howard Hughes Medical Institute, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

Keywords

Drug treatment, Hyperammonaemia, Longitudinal study, Survival, Urea cycle disorders

Correspondence

Marshall L Summar, M.D., Department of Pediatrics and Molecular Physiology & Biophysics, Center for Human Genetic Research and Division of Medical Genetics, Vanderbilt University Medical Center, 2215 Garland Ave., Suite 1175J Light Hall, Nashville, TN 37232-0007, USA.

Tel: +615-322-6947 |

Fax: +615-343-8619 |

Email: Marshall.summar@vanderbilt.edu

Received

27 December 2007; revised 2 June 2008; accepted 25 June 2008.

DOI:10.1111/j.1651-2227.2008.00952.x

The authors do not have a financial conflict of interest in the publication of this material.

Abstract

Aim: A large longitudinal interventional study of patients with a urea cycle disorder (UCD) in hyperammonaemic crisis was undertaken to amass a significant body of data on their presenting symptoms and survival.

Methods: Between 1982 and 2003, as part of the FDA approval process, data were collected on patients receiving an intravenous combination of nitrogen scavenging drugs (Ammonul[®] sodium phenylacetate and sodium benzoate (10%, 10%)) for the treatment of hyperammonaemic crises caused by urea cycle disorders.

Results: A final diagnosis of a UCD was made for 260 patients, representing 975 episodes of hospitalization. Only 34% of these patients presented within the first 30 days of life and had a mortality rate of 32%. The most common presenting symptoms were neurological (80%), or gastrointestinal (33%). This cohort is the largest collection of patients reported for these diseases and the first large cohort in the United States.

Conclusion: Surprisingly, the majority (66%) of patients with heritable causes of hyperammonaemia present beyond the neonatal period (>30 days). Patients with late-onset presenting disorders exhibited prolonged survival compared to the neonatal-presenting group.

INTRODUCTION

The urea cycle was first described in 1932 by Krebs and Henseleit (1). The urea cycle disorders (UCDs) result from defects in the clearance of excess nitrogen produced by the breakdown of protein and other nitrogen-containing molecules. The incidence of these disorders in the United States is roughly estimated to be at least 1/25 000 births but partial defects may mean that this number is much higher (2,3). In a Japanese study covering the period 1975–1995, the reported incidence was 1/46 000. Severe deficiency or total absence of activity of any of the first four enzymes in the urea cycle (carbamyl phosphate synthetase I, CPS-I; ornithine transcarbamylase, OTC; argininosuccinate synthetase, AS; argininosuccinate lyase, AL), or the cofactor producer N-acetyl glutamate synthase (NAGS), results in the accumulation of ammonia and other precursor metabolites during the first few days of life (4). In milder (or partial) urea cycle enzyme deficiencies, hyperammonaemia may be triggered by illness or stress at almost any time of life, resulting in multiple mild elevations of plasma ammonia concentration (5,6). In these cases, the hyperammonaemias are less severe and the symptoms more subtle than in the patients with early-onset disease.

The UCDs are considered a classic model for rare inborn errors of metabolism. Like many of these diseases, there are

few patients at any particular treatment centre, and incidence and demographic data are sketchy at best. There has been a relative degree of uniformity in the treatment of acute episodes of hyperammonaemia in patients with UCDs during the past twenty years. This treatment involved the use of intravenous sodium phenylacetate and intravenous sodium benzoate as scavengers of excess nitrogen (2). The open Investigational New Drug (number 17 123) study during this time (1982–2003) required enrolment of patients receiving intravenous drug for the treatment of an acute episode of hyperammonaemia. The study was limited primarily to patients with defects in the first three enzymes of the urea cycle (CPS-I, OTC, AS) with minimal inclusion of patients with arginase (ARG) deficiency or AL. As a part of the FDA approval process, a systematic chart review was done for these patients and data recorded on the presenting signs and symptoms, laboratory test parameters and any mortalities related to these hyperammonaemic incidents. This publication reports on the most comprehensive dataset in existence on these patients. Using this information we have developed statistics on the age of onset of disease for these patients, presenting symptoms, disease incidence for the first three enzyme defects of the urea cycle and associated mortality rates. These data provide evidence-based insights into the nature of this particular group of rare disorders and

Horizon Exhibit 2008

REGULAR ARTICLE

Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes

Marshall L Summar (Marshall.summar@vanderbilt.edu)¹, Dries Dobbelaere², Saul Brusilow³, Brendan Lee⁴

1.Vanderbilt University Medical Center, Nashville, TN, USA

2.Hospital University Medical Center of Lille, Lille Cedex, France

3.Johns Hopkins Medical Center, Baltimore, MD, USA

4.Howard Hughes Medical Institute, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

Keywords

Drug treatment, Hyperammonaemia, Longitudinal study, Survival, Urea cycle disorders

Correspondence

Marshall L Summar, M.D., Department of Pediatrics and Molecular Physiology & Biophysics, Center for Human Genetic Research and Division of Medical Genetics, Vanderbilt University Medical Center, 2215 Garland Ave., Suite 1175J Light Hall, Nashville, TN 37232-0007, USA.

Tel: +615-322-6947 |

Fax: +615-343-8619 |

Email: Marshall.summar@vanderbilt.edu

Received

27 December 2007; revised 2 June 2008; accepted 25 June 2008.

DOI:10.1111/j.1651-2227.2008.00952.x

The authors do not have a financial conflict of interest in the publication of this material.

Abstract

Aim: A large longitudinal interventional study of patients with a urea cycle disorder (UCD) in hyperammonaemic crisis was undertaken to amass a significant body of data on their presenting symptoms and survival.

Methods: Between 1982 and 2003, as part of the FDA approval process, data were collected on patients receiving an intravenous combination of nitrogen scavenging drugs (Ammonul[®] sodium phenylacetate and sodium benzoate (10%, 10%)) for the treatment of hyperammonaemic crises caused by urea cycle disorders.

Results: A final diagnosis of a UCD was made for 260 patients, representing 975 episodes of hospitalization. Only 34% of these patients presented within the first 30 days of life and had a mortality rate of 32%. The most common presenting symptoms were neurological (80%), or gastrointestinal (33%). This cohort is the largest collection of patients reported for these diseases and the first large cohort in the United States.

Conclusion: Surprisingly, the majority (66%) of patients with heritable causes of hyperammonaemia present beyond the neonatal period (> 30 days). Patients with late-onset presenting disorders exhibited prolonged survival compared to the neonatal-presenting group.

INTRODUCTION

The urea cycle was first described in 1932 by Krebs and Henseleit (1). The urea cycle disorders (UCDs) result from defects in the clearance of excess nitrogen produced by the breakdown of protein and other nitrogen-containing molecules. The incidence of these disorders in the United States is roughly estimated to be at least 1/25 000 births but partial defects may mean that this number is much higher (2,3). In a Japanese study covering the period 1975–1995, the reported incidence was 1/46 000. Severe deficiency or total absence of activity of any of the first four enzymes in the urea cycle (carbamyl phosphate synthetase I, CPS-I; ornithine transcarbamylase, OTC; argininosuccinate synthetase, AS; argininosuccinate lyase, AL), or the cofactor producer N-acetyl glutamate synthase (NAGS), results in the accumulation of ammonia and other precursor metabolites during the first few days of life (4). In milder (or partial) urea cycle enzyme deficiencies, hyperammonaemia may be triggered by illness or stress at almost any time of life, resulting in multiple mild elevations of plasma ammonia concentration (5,6). In these cases, the hyperammonaemias are less severe and the symptoms more subtle than in the patients with early-onset disease.

The UCDs are considered a classic model for rare inborn errors of metabolism. Like many of these diseases, there are

few patients at any particular treatment centre, and incidence and demographic data are sketchy at best. There has been a relative degree of uniformity in the treatment of acute episodes of hyperammonaemia in patients with UCDs during the past twenty years. This treatment involved the use of intravenous sodium phenylacetate and intravenous sodium benzoate as scavengers of excess nitrogen (2). The open Investigational New Drug (number 17 123) study during this time (1982–2003) required enrolment of patients receiving intravenous drug for the treatment of an acute episode of hyperammonaemia. The study was limited primarily to patients with defects in the first three enzymes of the urea cycle (CPS-I, OTC, AS) with minimal inclusion of patients with arginase (ARG) deficiency or AL. As a part of the FDA approval process, a systematic chart review was done for these patients and data recorded on the presenting signs and symptoms, laboratory test parameters and any mortalities related to these hyperammonaemic incidents. This publication reports on the most comprehensive dataset in existence on these patients. Using this information we have developed statistics on the age of onset of disease for these patients, presenting symptoms, disease incidence for the first three enzyme defects of the urea cycle and associated mortality rates. These data provide evidence-based insights into the nature of this particular group of rare disorders and

challenge some of the assumptions typically made about these patients.

SUBJECTS AND METHODS

The data source for this study was an open-label, uncontrolled study in patients with hyperammonaemia due to UCDs. Data collected from February 10, 1982 through May 31, 2003 were included in the analyses for this article; the study was closed on March 31, 2005 after marketing approval for sodium phenylacetate and sodium benzoate (NaPA/NaBZ) injection 10%/10% (Ammonul®, Ucylyd Pharma, Scottsdale, AZ, USA) was granted by the Food and Drug Administration (FDA). Patients were originally treated under an investigational new drug application (IND number 17 123) sponsored, prior to 1999, by Dr. Saul W. Brusilow of the Johns Hopkins School of Medicine; the IND was transferred to Ucylyd Pharma in 1999. Written informed consent, as appropriate for each institution, was obtained from each patient or their legal authorized representative. Institutional Review Board (IRB) approval was obtained as appropriate at that time at the treating institutions. To the best knowledge of the authors and other experts in the field, this study was the only significant source of drug available to treat these patients during the period of 1982 to 2003.

The original protocol called for the treatment of patients with CPS-I, OTC or AS deficiency, and not AL or ARG deficiency, and therefore the numbers for AL and ARG deficiency in this report do not reflect their true incidences in the patient population.

An episode was defined as a hospitalization for hyperammonaemia during which the patient received NaPA/NaBZ Injection 10%/10% as rescue treatment. Data collected as part of the FDA study included plasma ammonia levels and presenting signs and symptoms. Episodes described herein occurred at 115 hospitals in the United States and Canada.

Data were collected on patients only during their time in hospital and no data were collected on these patients in the intervals when they were discharged from the hospital.

A specific urea cycle diagnosis was made for each patient by the treating physician. Acceptable diagnostic methods used included liver biopsy with enzymatic analysis (all disorders), mutation analysis (all disorders), allopurinol challenge test combined with hyperammonaemia and plasma amino acid analysis (OTC and CPS-I), plasma amino acid analysis (AS and AL) and erythrocyte assay (ARG).

Statistical methods

The data presentation for this article consists of descriptive statistics including means, standard deviations and medians for continuous variables and frequency counts and percentages for categorical variables. Variation is reported as standard deviation. Missing data are excluded from the summaries and percentage calculations. Kaplan–Meier survival plots are also provided. Patients were censored at the hospital discharge date from the last episode experienced to avoid missing data errors. All data analyses were performed using SAS® (Cary, NC, USA) version 8.2.

RESULTS

Three hundred and sixteen patients were treated for 1045 episodes of hospitalization between 1982 and 2003; however, 56 patients did not have definitive final diagnoses of a specific UCD and were thus not included in the analyses for this article. A final diagnosis of a UCD was made for 260 patients, representing 975 episodes of hospitalization.

Patient diagnoses and age at presentation

The most frequent diagnosis was OTC deficiency in 142 of 260 patients (55%), followed by AS deficiency (citrullinaemia I) in 70 patients (27%), CPS-I deficiency in 36 patients (14%), AL deficiency in 7 patients (3%) and ARG deficiency in 2 patients (<1%).

Figure 1 shows the age of each patient at the first hospitalization for hyperammonaemia, by each UCD diagnosis and by all diagnoses. Overall, the median age at first




Figure 1 Number of patients by diagnosis and age at first episode. Each patient is counted once at the age the first episode of hyperammonaemia was reported.

presentation was 2.0 years and ranged from 1 day to 53 years. Of the total of 260 patients diagnosed with a UCD, 34% were aged 0 to 30 days, 18% were aged 31 days to 2 years, 28% were aged >2 to 12 years, 10% were aged >12 to 16 years, and 10% were older than 16 years.

The typical age at first presentation varied among the different diagnoses. Males with OTC deficiency tended to present earlier (median of approximately 6 months) than females (median age of 10 years). Of the 69 male patients with OTC deficiency, 46% presented at age 0 to 30 days, 19% at 31 days to 2 years, 22% at >2 to 12 years, and 13% at >12 years. As expected for this X-linked disorder, onset during infancy was the typical pattern; however, more than half of the males had late-onset OTC deficiency. Among the 73 female patients with OTC deficiency, onset during childhood or adolescence was the typical pattern, although only 4% presented at age 0 to 30 days, compared to 16% between the age of 31 days to 2 years, 51% at >2 to 12 years, 10% at >12 to 16 years, and 19% at >16 years.

For patients with CPS-I and AS deficiencies, there was no typical age at first presentation. For both of these disorders, the mean age of first presentation was during young childhood (median approximately 11 months) for CPS-I deficiency, and a median of 2.0 years for AS deficiency. Substantial percentages of patients had their first episodes at age 0 to 30 days (27% for CPS-I deficiency and 37% for AS deficiency), at 31 days to 2 years (30% for CPS-I and 14% for AS deficiency), and at >2 to 12 years (19% for CPS-I and 33% for AS deficiency).

For AL deficiency, five of seven patients presented at age 0 to 30 days, one patient at 6 years, and one patient at 14 years, and for ARG deficiency, one patient presented at 3 days and the other at 19 years.

Recurrence of hyperammonaemia

Figure 2 shows the number of hyperammonaemic episodes by diagnosis and by age. Many patients had multiple episodes of hyperammonaemia, and thus, overall, the total

number of hyperammonaemic episodes is far greater than the number of patients. For patients with AS or CPS-I deficiencies and males with OTC deficiency, approximately 70% of episodes occurred between the age of 31 days and 12 years. For females with OTC deficiency, 92% of episodes occurred at age >2 years.

Among patients with five or more reported episodes, the average number of episodes per year was 2.2 for patients with AS deficiency, 2.9 for males with OTC deficiency, 2.4 for females with OTC deficiency and 2.8 for patients with CPS-I deficiency. The number of episodes per year varied considerably among individual patients, ranging from 0.6 episodes per year in a patient with AS deficiency (nine episodes from the age of 3 to 17 years) to eight episodes per year in a female with OTC deficiency (32 episodes from the age of 18 to 21). One patient with CPS-I deficiency had eight hyperammonaemic episodes in the first year of life. The greatest number of episodes reported in any single patient was 77 in a female with OTC deficiency. She had an average of 3.5 episodes per year between the age of 2 and 23.

Signs and symptoms of a hyperammonaemic episode in patients with UCDs

Most hyperammonaemic episodes (58% of all episodes) were preceded by reported illness. Other known events preceding episodes included non-compliance with diet (15%), non-compliance with medication (10%), and major life events (such as surgery, accidents, school stress, pregnancy, etc.) (10%).

Presenting signs and symptoms of a hyperammonaemic episode are summarized in Table 1. In the majority of episodes (76%), patients already had neurological symptoms at the time of hospital admission. A decreased level of consciousness (symptoms included fatigue, lethargy, drowsiness, unresponsiveness, coma and obtundation), and/or abnormal motor function (symptoms included slurred speech, tremors, weakness, decreased or increased muscle tone and ataxia), were more frequent at the first episode than at




Figure 2 Number of episodes by diagnosis and age at first episode. Each patient with multiple episodes is counted multiple times at each age during which an episode of hyperammonaemia was reported.

Table 1 Frequency of presenting signs and symptoms

Symptom	No. of episodes		
	First episode n = 260	Subsequent episode n = 715	Any episode n = 975
Any	240 (92.3%)	670 (93.7%)	910 (93.3%)
Neurological	208 (80.0%)	532 (74.4%)	740 (75.9%)
Decreased level of consciousness	164 (63.1%)	365 (51.0%)	529 (54.3%)
Altered mental status	83 (31.9%)	268 (37.5%)	351 (36.0%)
Abnormal motor function	78 (30.0%)	155 (21.7%)	233 (23.9%)
Seizures	25 (9.6%)	34 (4.8%)	59 (6.1%)
Other*	17 (6.5%)	65 (9.1%)	82 (8.4%)
Gastrointestinal	85 (32.7%)	340 (47.6%)	425 (43.6%)
Vomiting	50 (19.2%)	242 (33.8%)	292 (29.9%)
Poor feeding	24 (9.2%)	75 (10.5%)	99 (10.2%)
Diarrhoea	9 (3.5%)	58 (8.1%)	67 (6.9%)
Nausea	9 (3.5%)	31 (4.3%)	40 (4.1%)
Constipation	0	9 (1.3%)	9 (0.9%)
Other†	13 (5.0%)	73 (10.2%)	86 (8.8%)
Co-morbid conditions	118 (45.4%)	299 (41.8%)	417 (42.8%)
Infection	75 (30.0%)	252 (35.2%)	330 (33.8%)
Respiratory	16 (6.2%)	57 (8.0%)	73 (7.5%)
Renal	17 (6.5%)	12 (1.7%)	29 (3.0%)
Cardiovascular	10 (3.8%)	3 (0.4%)	13 (1.3%)
Haematological	7 (2.7%)	6 (0.8%)	13 (1.3%)
Hepatic	3 (1.2%)	1 (0.1%)	4 (0.4%)
Other‡	15 (5.8%)	27 (3.8%)	42 (4.3%)
General/constitutional	35 (13.5%)	84 (11.7%)	119 (12.2%)
Fever	17 (3.5%)	56 (7.8%)	73 (7.5%)
Dehydration	11 (4.2%)	26 (3.6%)	37 (3.8%)
Hypothermia	5 (1.9%)	1 (0.1%)	6 (0.6%)
Weight loss	2 (0.8%)	2 (0.3%)	4 (0.4%)
Failure to thrive	0	1 (0.1%)	1 (0.1%)
Other§	2 (0.8%)	3 (0.4%)	5 (0.5%)
Routine check-up	0	18 (2.5%)	18 (1.8%)

*Includes headache, stroke, cerebral oedema, cerebral haemorrhage, cortical blindness, hemianopsia with scotoma and burning eyes.

†Includes abdominal pain, gastritis, duodenitis, ileus, gastro-oesophageal reflux, gastrointestinal (GI) dysmotility, intestinal obstruction, irritable bowel syndrome, pancreatitis, GI bleed, duodenal atresia, gastroparesis, pyloric ulcer and pyloric stenosis.

‡Includes rash, fracture, burn, surgery, cholelithiasis, ovarian cyst, hernia and necrosis of femoral heads.

§Includes hypovolaemia, paleness, puffiness and oedema.

subsequent episodes. Altered mental status (symptoms included irritability, tantrums, strange behaviour or speech, dizziness, confusion, agitation and combativeness) were slightly more frequent at subsequent episodes than at the first episode.

Other notable presenting signs and symptoms included infection (reported in 34% of episodes) and vomiting (30%). Both sets of signs and symptoms were somewhat more frequent at subsequent episodes than at the first episode, particularly vomiting.

It should also be noted that in some patients (18 hyperammonaemic episodes), an elevated plasma ammonia level, which received treatment, was noted during a routine office visit and was not accompanied by symptoms typical of hyperammonaemia. In 9 of the 18 episodes for which hyperammonaemia was discovered during a routine office visit, no other symptoms were reported, while in the other nine episodes, mild neurological symptoms, such as irritability, drowsiness or restlessness, were noted during neurological examination but had not been reported previously. It is possible that in these circumstances, the high levels of ammonia may reflect an artefact of specimen handling.

Survival of patients with UCDs

Figure 3 shows a Kaplan–Meier graph of survival by age at the first episode of hyperammonaemia. Survival time is calculated as the amount of time between the discharge date of the last episode and the admission date from the first episode. Patients who presented with the first hyperammonaemic episode at age between 0 and 30 days had the worst outcome—only 35% of patients were still alive at the final follow-up time point (approximately 11 years after the start of the study period). Of the 26 deaths that occurred in this group, 22 were within the first 2 months of life and only one patient after 3 years at the age of 6 years. Patients presenting in late infancy had the best outcome, with 87% remaining alive at the final follow-up time point. Only two patients in this group died, one at approximately 10 months of age and the other at approximately 2.5 years after the first episode. Of the patients presenting at >2 to 16 years of age, 78% were alive at the final follow-up time point. Ten of the 12 deaths in this group occurred within the first 50 days of initial presentation, one approximately 2 years later, and one approximately 7 years later.

Figure 4 shows a Kaplan–Meier graph of survival by diagnosis (data are not presented for AL and ARG). Percent survival at the final follow-up time point was 78% among patients with AS deficiency, 74% among females with OTC deficiency, 61% among patients with CPS-I deficiency, and 53% among males with OTC deficiency. For all diagnoses, most deaths occurred within the first 2 months of initial presentation (16 of 20 deaths for males with OTC deficiency, eight of nine deaths for females with OTC deficiency, four of seven deaths for patients with CPS-I deficiency, and five of six deaths for patients with AS deficiency).

DISCUSSION

This report is the second large overview of data collected from the United States on the incidence of UCDs combined with clinical presentation and outcome data, and is the largest report on UCDs to date. These data also reflect the survival rates using the current treatment methods available for hyperammonaemic crisis (nitrogen scavenging compounds). These data are surprising in the fact that they contradict the commonly held belief that UCDs are primarily disorders of the newborn period. As our data show, even when female OTC carriers are excluded, the most

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.